Percy Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Percy Lee has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Michael L. Steinberg
Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
3 shared publicationsRitchell van Dams
Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
3 shared publicationsAnn C. Raldow
Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
2 shared publicationsFang-I Chu
Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
2 shared publicationsMinsong Cao
Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
2 shared publicationsAmar U. Kishan
Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
1 shared publication
Latest Publications
- Open Access
- 24 September 2022
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 22 (1) , 1-8
Systematic endoscopic staging of mediastinum to determine impact on radiotherapy for locally advanced lung cancer (SEISMIC): protocol for a prospective single arm multicentre interventional study
Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is established as the preferred method of mediastinal lymph node (LN) staging in non-small cell lung cancer (NSCLC). Selective (targeted) LN sampling is most commonly performed however studies in early stage NSCLC and locally advanced NSCLC confirm systematic EBUS-TBNA evaluation improves accuracy of mediastinal staging. This study aims to establish the rate of detection of positron emission tomography (PET)-occult LN metastases following systematic LN staging by EBUS-TBNA, and to determine the utility of systematic mediastinal staging for accurate delineation of radiation treatment fields in patients with locally advanced NSCLC. Methods: Consecutive patients undergoing EBUS-TBNA for diagnosis/staging of locally advanced NSCLC will be enrolled in this international multi-centre single arm study. Systematic mediastinal LN evaluation will be performed, with all LN exceeding 6 mm to be sampled by TBNA. Where feasible, endoscopic ultrasound staging (EUS-B) may also be performed. Results of minimally invasive staging will be compared to FDG-PET. The primary end-point is proportion of patients in whom systematic LN staging identified PET-occult NSCLC metastases. Secondary outcome measures include (i) rate of nodal upstaging, (ii) false positive rate of PET for mediastinal LN assessment, (iii) analysis of clinicoradiologic risk factors for presence of PET-occult LN metastases, (iv) impact of systematic LN staging in patients with discrepant findings on PET and EBUS-TBNA on target coverage and dose to organs at risk (OAR) in patients undergoing radiotherapy. Discussion: With specificity of PET of 90%, guidelines recommend tissue confirmation of positive mediastinal LN to ensure potentially early stage patients are not erroneously denied potentially curative resection. However, while confirmation of pathologic LN is routinely sought, the exact extent of mediastinal LN involvement in NSCLC in patient with Stage III NSCLC is rarely established. Studies examining systematic LN staging in early stage NSCLC report a significant discordance between PET and EBUS-TBNA. In patients with locally advanced disease this has significant implications for radiation field planning, with risk of geographic miss in the event of PET-occult mediastinal LN metastases. The SEISMIC study will examine both diagnostic outcomes following systematic LN staging with EBUS-TBNA, and impact on radiation treatment planning. Trial registration: ACTRN12617000333314, ANZCTR, Registered on 3 March 2017.
- 24 September 2022
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 22 (1) , 1-8
Open AccessSystematic endoscopic staging of mediastinum to determine impact on radiotherapy for locally advanced lung cancer (SEISMIC): protocol for a prospective single arm multicentre interventional study
Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is established as the preferred method of mediastinal lymph node (LN) staging in non-small cell lung cancer (NSCLC). Selective (targeted) LN sampling is most commonly performed however studies in early stage NSCLC and locally advanced NSCLC confirm systematic EBUS-TBNA evaluation improves accuracy of mediastinal staging. This study aims to establish the rate of detection of positron emission tomography (PET)-occult LN metastases following systematic LN staging by EBUS-TBNA, and to determine the utility of systematic mediastinal staging for accurate delineation of radiation treatment fields in patients with locally advanced NSCLC. Methods: Consecutive patients undergoing EBUS-TBNA for diagnosis/staging of locally advanced NSCLC will be enrolled in this international multi-centre single arm study. Systematic mediastinal LN evaluation will be performed, with all LN exceeding 6 mm to be sampled by TBNA. Where feasible, endoscopic ultrasound staging (EUS-B) may also be performed. Results of minimally invasive staging will be compared to FDG-PET. The primary end-point is proportion of patients in whom systematic LN staging identified PET-occult NSCLC metastases. Secondary outcome measures include (i) rate of nodal upstaging, (ii) false positive rate of PET for mediastinal LN assessment, (iii) analysis of clinicoradiologic risk factors for presence of PET-occult LN metastases, (iv) impact of systematic LN staging in patients with discrepant findings on PET and EBUS-TBNA on target coverage and dose to organs at risk (OAR) in patients undergoing radiotherapy. Discussion: With specificity of PET of 90%, guidelines recommend tissue confirmation of positive mediastinal LN to ensure potentially early stage patients are not erroneously denied potentially curative resection. However, while confirmation of pathologic LN is routinely sought, the exact extent of mediastinal LN involvement in NSCLC in patient with Stage III NSCLC is rarely established. Studies examining systematic LN staging in early stage NSCLC report a significant discordance between PET and EBUS-TBNA. In patients with locally advanced disease this has significant implications for radiation field planning, with risk of geographic miss in the event of PET-occult mediastinal LN metastases. The SEISMIC study will examine both diagnostic outcomes following systematic LN staging with EBUS-TBNA, and impact on radiation treatment planning. Trial registration: ACTRN12617000333314, ANZCTR, Registered on 3 March 2017.
- 29 July 2022
- Published by Springer Nature
- p. 1049-1058
Image-Guided Radiotherapy in Lung Cancer
- 1 May 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 170, 14-20
Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: A prospective phase I trial
- 1 May 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 170, 14-20
Ablative radiotherapy for liver tumors using stereotactic MRI-guidance: A prospective phase I trial
- 4 September 2021
- Published by Springer Nature in Current Colorectal Cancer Reports
- Vol. 17 (5) , 69-76
Role of MR-guided Radiotherapy (MRgRT) in Colorectal Cancer
- 4 September 2021
- Published by Springer Nature in Current Colorectal Cancer Reports
- Vol. 17 (5) , 69-76
Role of MR-guided Radiotherapy (MRgRT) in Colorectal Cancer
- Open Access
- 20 July 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (17) , 5897-5906
Clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis
Purpose: Stereotactic body radiotherapy (SBRT) delivers ablative doses with excellent local control. However, implementing SBRT for abdominal and pelvic tumors has been limited by the risk for treatment‐related gastrointestinal toxicity. MRI‐guided radiotherapy may ameliorate these risks and increase the therapeutic ratio. We report the clinical outcomes of stereotactic MRI‐guided adaptive radiotherapy (SMART) for primary and metastatic tumors in the abdomen and pelvis.Methods: From November 2014 to August 2017, the first 106 consecutive patients with 121 tumors in the abdomen and pelvis were treated with SMART at a single institution. Of the cohort, 41.5%, 15.1%, and 43.4% had primary, locally recurrent, and oligometastatic tumors, respectively. SMART was delivered using a tri‐cobalt‐60 gantry with on‐board 0.35 Tesla MRI with respiratory breath‐hold and daily adaptive re‐planning when anatomically necessary. A median of 40Gy in five fractions was prescribed. The Common Terminology Criteria for Adverse Events v.4.03 was used to score treatment‐related toxicities. Local control (LC), progression‐free survival (PFS), and overall survival (OS) were estimated using Kaplan–Meier method.Results: Of the 510 treatments, seventy‐one (13.9%) were adapted. Fatigue, nausea, and pain were the most common acute toxicities. 0.9 and 0% of patients experienced acute grade three and four toxicities, respectively. 5.2 and 2.1% of patients experienced late grade three and four toxicities, respectively. After a median follow‐up of 20.4 months, the 2‐year LC rate was 74% on a per‐lesion basis. Two‐year LC was 96% for lesions that were treated with BED10≥100 versus 69% for BED10p = 0.02). PFS was significantly different between patients with and without locally controlled tumors (2‐year PFS 21 vs. 8%, p = 0.03). Two‐year OS was 57% for the entire cohort.Conclusions: Favorable LC and PFS outcomes were observed with minimal morbidity for tumors in the abdomen and pelvis treated with SMART. Future prospective clinical trials to validate these findings are warranted.
- 20 July 2021
- Published by Wiley in Cancer Medicine
- Vol. 10 (17) , 5897-5906
Open AccessClinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis
Purpose: Stereotactic body radiotherapy (SBRT) delivers ablative doses with excellent local control. However, implementing SBRT for abdominal and pelvic tumors has been limited by the risk for treatment‐related gastrointestinal toxicity. MRI‐guided radiotherapy may ameliorate these risks and increase the therapeutic ratio. We report the clinical outcomes of stereotactic MRI‐guided adaptive radiotherapy (SMART) for primary and metastatic tumors in the abdomen and pelvis.Methods: From November 2014 to August 2017, the first 106 consecutive patients with 121 tumors in the abdomen and pelvis were treated with SMART at a single institution. Of the cohort, 41.5%, 15.1%, and 43.4% had primary, locally recurrent, and oligometastatic tumors, respectively. SMART was delivered using a tri‐cobalt‐60 gantry with on‐board 0.35 Tesla MRI with respiratory breath‐hold and daily adaptive re‐planning when anatomically necessary. A median of 40Gy in five fractions was prescribed. The Common Terminology Criteria for Adverse Events v.4.03 was used to score treatment‐related toxicities. Local control (LC), progression‐free survival (PFS), and overall survival (OS) were estimated using Kaplan–Meier method.Results: Of the 510 treatments, seventy‐one (13.9%) were adapted. Fatigue, nausea, and pain were the most common acute toxicities. 0.9 and 0% of patients experienced acute grade three and four toxicities, respectively. 5.2 and 2.1% of patients experienced late grade three and four toxicities, respectively. After a median follow‐up of 20.4 months, the 2‐year LC rate was 74% on a per‐lesion basis. Two‐year LC was 96% for lesions that were treated with BED10≥100 versus 69% for BED10p = 0.02). PFS was significantly different between patients with and without locally controlled tumors (2‐year PFS 21 vs. 8%, p = 0.03). Two‐year OS was 57% for the entire cohort.Conclusions: Favorable LC and PFS outcomes were observed with minimal morbidity for tumors in the abdomen and pelvis treated with SMART. Future prospective clinical trials to validate these findings are warranted.
- 1 February 2021
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (2) , e2034074
Assessment of Toxic Effects Associated With Dose-Fractionated Radiotherapy Among Patients With Cancer and Comorbid Collagen Vascular Disease
Collagen vascular disease (CVD) is a heterogeneous group of disorders characterized by the presence of autoantibodies and a dysregulated immune system. Patients with CVD have genetic polymorphisms that, together with environmental triggers, produce widespread inflammation that is associated with injury to connective tissues.1 Many patients with CVD have a higher baseline risk of developing site-specific cancers; thus, an increasing proportion of patients is expected to develop cancer as life expectancies increase with the use of new therapies.2-8 At least 50% of all patients with cancer require radiotherapy as part of their care; however, some oncologists have considered a diagnosis of CVD to be a relative contraindication to radiotherapy because of concerns about severe treatment-associated toxic effects.9,10
- 1 February 2021
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (2) , e2034074
Assessment of Toxic Effects Associated With Dose-Fractionated Radiotherapy Among Patients With Cancer and Comorbid Collagen Vascular Disease
Collagen vascular disease (CVD) is a heterogeneous group of disorders characterized by the presence of autoantibodies and a dysregulated immune system. Patients with CVD have genetic polymorphisms that, together with environmental triggers, produce widespread inflammation that is associated with injury to connective tissues.1 Many patients with CVD have a higher baseline risk of developing site-specific cancers; thus, an increasing proportion of patients is expected to develop cancer as life expectancies increase with the use of new therapies.2-8 At least 50% of all patients with cancer require radiotherapy as part of their care; however, some oncologists have considered a diagnosis of CVD to be a relative contraindication to radiotherapy because of concerns about severe treatment-associated toxic effects.9,10
- 25 May 2020
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 41 (03) , 333-334
Lung Cancer: Advances in Diagnosis and Management
In this issue of Seminars in Respiratory and Critical Care Medicine, leading researchers from around the world provide state-of-the-art review on impactful topics related to the clinical management of lung cancer. As lung cancer has been a devastatingly challenging disease to treat that requires multidisciplinary management to achieve optimal outcomes, this issue focuses broadly on advances in diagnosis and treatment from the thoracic surgery, radiation oncology, and medical oncology perspectives. From the thoracic surgery perspective, the landscape of care for early stage nonsmall cell lung cancer (NSCLC) is rapidly evolving, even though progress is less dramatic than what has occurred for advanced disease in recent years, There are continuous improvements in our ability to diagnose disease earlier, stage it more accurately, and improve the tolerability of treatment. The 2011 publication from the National Lung Screening Trial led to Center for Medicare & Medicaid Services (CMS) reimbursement for low-dose computer tomography (LDCT) screening for lung cancer in high risk cohorts in 2015. Recent results from European screening trials have furthered the excitement regarding the immense potential of LDCT screening to decrease lung cancer mortality. Efforts now focus on heavily implementation strategies, as only a fraction of eligible individuals undergoing screening. Resections for early stage NSCLC continue to become safer and more tolerable. The majority of stage-I cancer resections are currently performed via minimally invasive techniques, robotic, or video-assisted. The ability to perform anatomic lung resection with small incisions and without rib-spreading significantly decreases perioperative pain, complications, length of stay, and time to recovery without negatively impacting long-term oncologic outcome. Minimally invasive surgery is finally becoming the standard of care for stage-I NSCLC treatment. Efforts to improve tolerability of lung cancer resections extend throughout the perioperative period. Enhanced recovery pathways are revolutionizing surgical care, focusing on smoking cessation, minimally invasive approaches, decreased fasting, opioid-sparing analgesia, early mobilization, and increased patient education. These programs not only decrease opioid use, length of stay, and cardiopulmonary complications but also help to facilitate additional oncologic therapies. In locally advanced disease, there is continued evidence for the value of resection as part of a multimodality approach in selected populations and incredible excitement generated by induction strategies which now include immunotherapies. From the radiation oncology perspective, there has been tremendous excitement in the synergy between novel immunotherapeutics and radiation therapy. As radiation therapy remains an important modality for the treatment of medically inoperable early stage, local regionally advanced, and metastatic lung cancer, understanding the potential synergistic effects between novel biologics and immunotherapy with radiation therapy is critical. There is encouraging early preclinical and clinical data from combining immunotherapy and radiotherapy that will require further explorations to understand its underlying mechanisms and implications for this novel dual therapy. Several early clinical studies and post hoc analyses are supporting a growing body of evidence in combining radiation and immunotherapy for the treatment of lung cancer from early stage to metastatic disease. A second topic of interest is the emerging role of local therapies such as radiation and surgery for patients with oligometastatic or oligoprogressive disease status in lung cancer. The oligometastatic paradigm, which was proposed in the early 90's, hypothesized in some patients that metastatic disease is confined to a small number of sites. It is further postulated that gaining control of these oligometastatic sites may lead to potential cures for this subset of lung cancer patients. Several recent randomized phase-II studies support the use of ablative therapies for oligometastatic lung cancer. They suggest an improvement in progression free and overall survival when oligometastatic disease sites are consolidated with local therapies. Larger phase-III validation studies are currently ongoing, as well as smaller trials, exploring ablative therapies for polymetastatic lung cancer. Finally, yet importantly, there has been an increase in use of patient-reported outcome (PRO) measures in lung cancer clinical trials. Studies have shown that PROs may be better prognostic factors for survival compared with traditional factors such as performance status. PROs in recent large immunotherapy trials in lung cancer find that PROs are improved with immunotherapy compared with chemotherapy, showing an improvement in quality of life, as well as extension of life, with immunotherapy. This review will also underscore the current state of the science in PRO research including challenges of applying appropriate PROs in future clinical trials. From the medical oncology perspective, the last 5 years have seen dramatic improvements in immunologic and targeted approaches to systemic lung cancer care, leading to both improved survival and enhanced quality of life. They have transformed the treatment landscape for non-small cell lung cancer and made the first steps in improving small cell lung cancer outcomes that we have had in more than 3 decades. Several immune checkpoint inhibitors have been FDA-approved for NSCLC, as monotherapy or in combination with chemotherapy. Not only does immunotherapy improve short-term parameters such as response rate, it also leads to a very durable response in as many as a quarter of patients, with survival extending beyond 5 years in some sizable subgroups. Modern targeted therapies, usually orally-available tyrosine kinase inhibitors, have been applied to oncogene driven subsets of NSCLC, frequently with response...
- 25 May 2020
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 41 (03) , 333-334
Lung Cancer: Advances in Diagnosis and Management
In this issue of Seminars in Respiratory and Critical Care Medicine, leading researchers from around the world provide state-of-the-art review on impactful topics related to the clinical management of lung cancer. As lung cancer has been a devastatingly challenging disease to treat that requires multidisciplinary management to achieve optimal outcomes, this issue focuses broadly on advances in diagnosis and treatment from the thoracic surgery, radiation oncology, and medical oncology perspectives. From the thoracic surgery perspective, the landscape of care for early stage nonsmall cell lung cancer (NSCLC) is rapidly evolving, even though progress is less dramatic than what has occurred for advanced disease in recent years, There are continuous improvements in our ability to diagnose disease earlier, stage it more accurately, and improve the tolerability of treatment. The 2011 publication from the National Lung Screening Trial led to Center for Medicare & Medicaid Services (CMS) reimbursement for low-dose computer tomography (LDCT) screening for lung cancer in high risk cohorts in 2015. Recent results from European screening trials have furthered the excitement regarding the immense potential of LDCT screening to decrease lung cancer mortality. Efforts now focus on heavily implementation strategies, as only a fraction of eligible individuals undergoing screening. Resections for early stage NSCLC continue to become safer and more tolerable. The majority of stage-I cancer resections are currently performed via minimally invasive techniques, robotic, or video-assisted. The ability to perform anatomic lung resection with small incisions and without rib-spreading significantly decreases perioperative pain, complications, length of stay, and time to recovery without negatively impacting long-term oncologic outcome. Minimally invasive surgery is finally becoming the standard of care for stage-I NSCLC treatment. Efforts to improve tolerability of lung cancer resections extend throughout the perioperative period. Enhanced recovery pathways are revolutionizing surgical care, focusing on smoking cessation, minimally invasive approaches, decreased fasting, opioid-sparing analgesia, early mobilization, and increased patient education. These programs not only decrease opioid use, length of stay, and cardiopulmonary complications but also help to facilitate additional oncologic therapies. In locally advanced disease, there is continued evidence for the value of resection as part of a multimodality approach in selected populations and incredible excitement generated by induction strategies which now include immunotherapies. From the radiation oncology perspective, there has been tremendous excitement in the synergy between novel immunotherapeutics and radiation therapy. As radiation therapy remains an important modality for the treatment of medically inoperable early stage, local regionally advanced, and metastatic lung cancer, understanding the potential synergistic effects between novel biologics and immunotherapy with radiation therapy is critical. There is encouraging early preclinical and clinical data from combining immunotherapy and radiotherapy that will require further explorations to understand its underlying mechanisms and implications for this novel dual therapy. Several early clinical studies and post hoc analyses are supporting a growing body of evidence in combining radiation and immunotherapy for the treatment of lung cancer from early stage to metastatic disease. A second topic of interest is the emerging role of local therapies such as radiation and surgery for patients with oligometastatic or oligoprogressive disease status in lung cancer. The oligometastatic paradigm, which was proposed in the early 90's, hypothesized in some patients that metastatic disease is confined to a small number of sites. It is further postulated that gaining control of these oligometastatic sites may lead to potential cures for this subset of lung cancer patients. Several recent randomized phase-II studies support the use of ablative therapies for oligometastatic lung cancer. They suggest an improvement in progression free and overall survival when oligometastatic disease sites are consolidated with local therapies. Larger phase-III validation studies are currently ongoing, as well as smaller trials, exploring ablative therapies for polymetastatic lung cancer. Finally, yet importantly, there has been an increase in use of patient-reported outcome (PRO) measures in lung cancer clinical trials. Studies have shown that PROs may be better prognostic factors for survival compared with traditional factors such as performance status. PROs in recent large immunotherapy trials in lung cancer find that PROs are improved with immunotherapy compared with chemotherapy, showing an improvement in quality of life, as well as extension of life, with immunotherapy. This review will also underscore the current state of the science in PRO research including challenges of applying appropriate PROs in future clinical trials. From the medical oncology perspective, the last 5 years have seen dramatic improvements in immunologic and targeted approaches to systemic lung cancer care, leading to both improved survival and enhanced quality of life. They have transformed the treatment landscape for non-small cell lung cancer and made the first steps in improving small cell lung cancer outcomes that we have had in more than 3 decades. Several immune checkpoint inhibitors have been FDA-approved for NSCLC, as monotherapy or in combination with chemotherapy. Not only does immunotherapy improve short-term parameters such as response rate, it also leads to a very durable response in as many as a quarter of patients, with survival extending beyond 5 years in some sizable subgroups. Modern targeted therapies, usually orally-available tyrosine kinase inhibitors, have been applied to oncogene driven subsets of NSCLC, frequently with response...
- 25 May 2020
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 41 (03) , 360-368
Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer—A Stimulating Partnership
Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer and the leading cause of cancer-related death. Although durable local control rates are high after surgical resection or definitive radiotherapy for early-stage disease, a substantial proportion of these patients eventually experience regional and/or distant failure and succumb to their metastatic disease. The discovery of immunotherapeutics and targeted biologics has revolutionized the treatment of locally advanced and metastatic disease, improving progression-free and overall survival when incorporated with the current standards of care. Notably, post-hoc analyses and early clinical trials provide a growing body of evidence to support a synergistic effect between radiation and immunotherapy for the treatment of NSCLC from early-stage to metastatic disease. Radiotherapy appears to be capable of not only potentiating the effect of immunotherapy in targeted lesions, but also eliciting an antitumor response in distant lesions without any direct exposure to radiation. This review explores the biologic basis of immunotherapy, targeted biologics, and radiotherapy as well as the preclinical and clinical data that support the combined use of radioimmunotherapy for early-stage, locally advanced, and metastatic NSCLC.
- 25 May 2020
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 41 (03) , 360-368
Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer—A Stimulating Partnership
Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer and the leading cause of cancer-related death. Although durable local control rates are high after surgical resection or definitive radiotherapy for early-stage disease, a substantial proportion of these patients eventually experience regional and/or distant failure and succumb to their metastatic disease. The discovery of immunotherapeutics and targeted biologics has revolutionized the treatment of locally advanced and metastatic disease, improving progression-free and overall survival when incorporated with the current standards of care. Notably, post-hoc analyses and early clinical trials provide a growing body of evidence to support a synergistic effect between radiation and immunotherapy for the treatment of NSCLC from early-stage to metastatic disease. Radiotherapy appears to be capable of not only potentiating the effect of immunotherapy in targeted lesions, but also eliciting an antitumor response in distant lesions without any direct exposure to radiation. This review explores the biologic basis of immunotherapy, targeted biologics, and radiotherapy as well as the preclinical and clinical data that support the combined use of radioimmunotherapy for early-stage, locally advanced, and metastatic NSCLC.